Galvani D W, Nethersell A B, Cawley J C
Department of Haematology, University of Liverpool, U.K.
Leuk Res. 1988;12(3):257-62. doi: 10.1016/0145-2126(88)90144-0.
A total of 15 patients with myelodysplastic states (MDS) were studied. Of the eight patients treated with alpha-interferon (alpha IFN) (3 megaunits/day for up to 6 months), one patient with refractory anaemia with excess blasts (RAEB) underwent an almost complete response while one case of chronic myelomonocytic leukaemia (CMML) showed a reduction in monocyte count; no improvement was observed in refractory anaemia (RA) or refractory anaemia with excess blasts in transformation (trRAEB). In all patients Leu7+ and Leu11a+ phenotypic natural killer (NK) cells were consistently normal in percentage numbers but functional NK activity was consistently reduced in all MDS subgroups. NK activity was enhanced by exposure to alpha IFN in vitro, but was very variable in patients being treated with the agent. There was no correlation between clinical response and changed NK activity in patients receiving alpha IFN. It is concluded that NK cells are unlikely to play a central role in the biology of myelodysplasia.
共对15例骨髓增生异常综合征（MDS）患者进行了研究。在8例接受α-干扰素（α IFN）治疗（300万单位/天，持续6个月）的患者中，1例伴有过多原始细胞的难治性贫血（RAEB）患者获得了几乎完全缓解，1例慢性粒-单核细胞白血病（CMML）患者单核细胞计数减少；难治性贫血（RA）或转化中的伴有过多原始细胞的难治性贫血（trRAEB）患者未观察到改善。所有患者中，Leu7 +和Leu11a +表型的自然杀伤（NK）细胞百分比数量始终正常，但在所有MDS亚组中，功能性NK活性始终降低。体外暴露于α IFN可增强NK活性，但在接受该药物治疗的患者中变化很大。接受α IFN治疗的患者临床反应与NK活性变化之间无相关性。结论是，NK细胞不太可能在骨髓增生异常的生物学过程中起核心作用。
